When It's Too Late to Join a Clinical Trial and the New Drug Selinexor with Dr. Nikoletta Lendvai, MD, PhD, MKSCC
![When It's Too Late to Join a Clinical Trial and the New Drug Selinexor with Dr. Nikoletta Lendvai, MD, PhD, MKSCC image](https://healthtree.org/images-resize?width=1000&height=1000&imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fcommunity%25252Fpublic%25252Fshared%25252Fimages-resize-7_b2864def-c7b2-48ee-82fb-f45106223171.jpeg%253Falt%253Dmedia)
When It's Too Late to Join a Clinical Trial and the New Drug Selinexor with Dr. Nikoletta Lendvai, MD, PhD, MKSCC
Event Description
Nikoletta Lendvai, MD, PhD Memorial Sloan Kettering Cancer Center Interview Date: October 28, 2016
Why should patients participate in clinical trials and is it ever too late to join one? Dr. Lendvai tells us that every stage is a good time to consider clinical trials, but when you've run out of options isn't one of them. She shares insight into the details of joining clinical trials (like who pays) and discusses the new drug in clinical trial - selinexor - as an example. This drugs is now being used to help patients who have become refractory to proteasome inhibitors like Velcade and iMiDs like Revlimid. In early studies, it looks like this drug can make many patients sensitive again to these prior treatment options. Dr. Lendvai shares clinical trials open at MSKCC for newly diagnosed patients, smoldering myeloma patients, clinical trials for transplants and for relapsed/refractory patients. It is very clear that going to an academic myeloma center gives patients a large number of options to take advantage of newer treatments that have not yet been approved.
Thanks to our episode sponsor
Schedule & Agenda
Speakers & Moderators
![The panelist Jennifer Ahlstrom](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/community%2Fpublic%2Fshared%2FJenny%20Bio%20300x300.jpg?alt=media)
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
![Johnson and Johnson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJohnson%20&%20Johnson%20Logo_64b18f59-85c9-4c20-a5ff-3842e69d8066.jpg?alt=media)
![Sanofi](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FSanofi%20updated%202023_d25a8d12-4f09-410c-9eb1-1e725b0b7c3e.jpg?alt=media)
![Pfizer](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPfizer%20Logo%202024_50ae4587-5fdc-48e2-9a52-21651c643494.png?alt=media)
![Genentech](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/admin%2Fpublic%2Fshared%2FGenentech_Logo-700x182_e3c64168-dcf4-4540-9e9d-26500b26920a.png?alt=media)
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_dec43aa4-fe53-4d5a-9b7f-4170101b47f9.webp?alt=media)
![Adaptive](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FAdaptive%20Logo%204.2023_e0d11d37-8b31-4c88-a0fc-4d07efc9b16b.png?alt=media)